The role of CXCL10-CXCR3 axis in the compounding effects of diabetes mellitus in periodontitis

CXCL10-CXCR3轴在糖尿病牙周炎复合作用中的作用

基本信息

  • 批准号:
    10740433
  • 负责人:
  • 金额:
    $ 43.22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-08-01 至 2025-07-31
  • 项目状态:
    未结题

项目摘要

Abstract Poorly controlled diabetes mellitus (DM) exacerbates periodontitis (PD) development and progression. In addition, the management of PD in patients with uncontrolled DM remains a clinical challenge. In fact, PD constitutes the sixth most frequent complication of DM. However, the mechanisms by which DM compounds PD are not fully understood, although a heightened inflammatory response plays a central role. Among the major inflammatory mediators of DM is CXCL10. Interestingly, CXCL10 also plays an important role in PD. CXCL10 expression levels are higher in periodontally diseased tissues and in the serum of patients with PD. Moreover, our laboratory has shown that the CXCL10-CXCR3 axis is fundamental for PD development. We demonstrated that experimentally-induced periodontal bone loss (EPD), in mice, is significantly reduced when the CXCL10 receptor CXCR3, is deleted. Moreover, systemic, and local delivery of a CXCR3 antagonist attenuates EPD, pointing to the targeting of CXCL10 as a potential intervention for PD. Given that DM exacerbates PD, and the key role of CXCL10 as an inflammatory mediator of DM and PD, we hypothesize that CXCL10 is central in mediating the detrimental effects of DM and PD. Thus, targeting the CXCL10-CXCR3 axis should ameliorate the deleterious effects of DM in the periodontium and is a potential therapeutic strategy for the periodontal management of patients with uncontrolled DM. To accomplish our goal, we have two specific aims (SA). SA1: Further elucidate the role of CXCL10 in the periodontium by deleting CXCL10 (SA1a) and by administering CXCL10 systemically (SA1b). SA2: Determine the inhibition of periodontal destruction by a CXCR3 antagonist in mice with DM. In this aim, we will evaluate if local delivery of nanoparticles containing a CXCR3 antagonist, AMG-487, could mitigate the effects of DM in the PD. In brief, DM will be induced in mice, EPD will be developed, and AMG-487 will be delivered locally in slow-releasing nanoparticles. These experiments will provide proof-of- principle evidence for targeting CXCL10-CXCR3 signaling in periodontal inflammation in patients with DM. The long-term goal of our research is to dissect the role of CXCL10 in the exacerbation of PD by DM and to lay the foundation for developing a novel therapeutic approach to assist in the periodontal treatment of patients with uncontrolled diabetes.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Flavia Pirih其他文献

Flavia Pirih的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Flavia Pirih', 18)}}的其他基金

Genomewide association studies in peri-implant bone loss
种植体周围骨丢失的全基因组关联研究
  • 批准号:
    10351903
  • 财政年份:
    2022
  • 资助金额:
    $ 43.22万
  • 项目类别:
Genomewide association studies in peri-implant bone loss
种植体周围骨丢失的全基因组关联研究
  • 批准号:
    10557131
  • 财政年份:
    2022
  • 资助金额:
    $ 43.22万
  • 项目类别:
Mouse Genome-Wide Association Studies in LPS-Induced Bone Loss
LPS 引起的骨丢失的小鼠全基因组关联研究
  • 批准号:
    8772724
  • 财政年份:
    2014
  • 资助金额:
    $ 43.22万
  • 项目类别:

相似海外基金

A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
  • 批准号:
    24K02286
  • 财政年份:
    2024
  • 资助金额:
    $ 43.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
  • 批准号:
    2420924
  • 财政年份:
    2024
  • 资助金额:
    $ 43.22万
  • 项目类别:
    Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
  • 批准号:
    10596047
  • 财政年份:
    2023
  • 资助金额:
    $ 43.22万
  • 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
  • 批准号:
    10742028
  • 财政年份:
    2023
  • 资助金额:
    $ 43.22万
  • 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
  • 批准号:
    BB/X017540/1
  • 财政年份:
    2023
  • 资助金额:
    $ 43.22万
  • 项目类别:
    Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
  • 批准号:
    LP210301365
  • 财政年份:
    2023
  • 资助金额:
    $ 43.22万
  • 项目类别:
    Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
  • 批准号:
    10730832
  • 财政年份:
    2023
  • 资助金额:
    $ 43.22万
  • 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
  • 批准号:
    10659841
  • 财政年份:
    2023
  • 资助金额:
    $ 43.22万
  • 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
  • 批准号:
    BB/V016067/1
  • 财政年份:
    2022
  • 资助金额:
    $ 43.22万
  • 项目类别:
    Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
  • 批准号:
    576545-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 43.22万
  • 项目类别:
    Idea to Innovation
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了